Marksans Pharma soars after Q4 PAT jumps 64% YoY
Mumbai, May 26 -- On a consolidated basis, the company reported a net profit of Rs 148.12 crore in Q4 FY26, up 63.60% YoY and 30.85% QoQ.
Revenue from operations rose 20.84% YoY to Rs 856.11 crore in Q4 FY26, while increasing 13.48% QoQ.
Gross profit stood at Rs 465.5 crore in Q4 FY26, up 21.5% YoY and 6.2% QoQ. Gross margin improved to 54.4% from 54.1% in Q4 FY25, supported by favourable product mix, softening raw material prices and forex tailwinds.
Profit before tax stood at Rs 199.99 crore in Q4 FY26, up 72.27% YoY and 32.78% QoQ.
EBITDA stood at Rs 195.4 crore in Q4 FY26, up 54% YoY and 21.6% QoQ. EBITDA margin expanded sharply to 22.8% from 17.9% in the year-ago period and 21.3% in Q3 FY26, aided by operating leverage and tight ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.